Glenn P. Bilawsky is the Chief Executive Officer of Discovery Life Sciences, the global market leader in biospecimen analysis and procurement to the global pharmaceutical, biotechnology, and diagnostics industries. He started his life sciences career in 1979 at McNeil Pharmaceutical, a division of Johnson and Johnson and brings more than four decades of experience in pharmaceutical, sales, marketing, and research and development, contract research and health economics services to Discovery.

Since 2000, he has established and sustained the aggressive growth of four companies that employed as many as 4,000 staff worldwide; these included privately held companies and a global division of UnitedHealth Group. Glenn has participated in the acquisition of over 40 companies and the successful sale of three. Prior to joining Discovery Life Sciences, Mr. Bilawsky held CEO positions at Precision Health Economics, the i3 division of UnitedHealth Group, and INC Research, now
Syneos Health.

He also held senior executive positions at Quintiles, Inc., now IQVIA, Inc., and Pharmaco LSR, now PPD, Inc.

Danny Zheng has held CEO and CFO positions in several public companies listed at the NYSE, American Stock Exchange (merged into NYSE), and OTC Markets. Danny has extensive experience in managing complex global entities, business development and transformation, finance, and SEC compliance in the information technology, consumer product, and hedge fund industries. Most recently, Danny was the CEO of GlassBridge Enterprises, Inc. a public traded investment advisor focusing on technology-driven quantitative funds.

In Danny’s early career, he worked in the computer motherboard industry and served as general manager of the Latin American region for a major brand. During his tenure, he established distribution channels throughout the Latin American region and pioneered a motherboard manufacturing facility in the Brazil free trade zone – Manaus, Amazonas.

Danny holds an MBA degree from the Wharton School at the University of Pennsylvania and a Bachelor of Arts in Accounting from Nankai University (China). Danny is also a Certified Public Accountant.

Valerie Goodwin-Adams, CRO, joined AllCells in 2018 to develop and lead AllCells’ marketing, sales, and customer success strategies. Valerie brings over 25 years of extensive top-line revenue-generating experience in FDA-regulated, biopharma, and medical device industries to AllCells. Prior to joining AllCells, Valerie served as the Sr. Director of Global Marketing and Development at Abaxis Global Diagnostics (acquired by Zoetis for 2.2B) for 13 years, where she built a Global Diagnostic Direct Sales, Product Management and Marketing Teams. Valerie has held product marketing and sales development positions of increasing responsibility at Agilent Technologies, Dako Cytomation, and Cadence Design Systems.

Valerie holds a B.A. in Communications from San Jose State University, CA, and an MBA from Brigham Young University (BYU) Marriott School of Business, UT. In addition, Valerie holds a Digital Marketing Certificate from Cornell University and an Advanced Global Leadership Certificate from Lucas Graduate School of Business.

Tiffany O. Salas-Morris is the Senior Vice President of Marketing for Discovery Life Sciences (DLS), the company of Biospecimen and Biomarker Specialists^™, combining the world’s largest commercial biospecimen inventory and procurement network with preeminent multi-omic biomarker service laboratories and cell-based solutions to help advance new therapies for cancer, infectious disease, and other rare and complex conditions. In 2003, Tiffany started her life sciences career as a Senior Assistant Scientist at Ambion, now a Thermo Fisher company. Since then, she has used her strong scientific and technical background to make an impact in various commercial, corporate, and clinical roles at global diagnostic companies, life science companies, contract research organizations, and specialty contract laboratories including PPD, Myriad RBM (now a Q2 company), Crown Bioscience and med fusion (now a Quest Diagnostics company). She brings DLS nearly 15 years of leadership experience in marketing, corporate strategy, and product development. Tiffany has been an integral leader at DLS for 4 years, helping achieve its aggressive growth objectives and is committed to helping DLS deliver the market’s most innovative suite of solutions to help scientists accelerate precision medicine programs throughout every stage of development. Tiffany obtained a Master of Science in Biotechnology from Johns Hopkins University and holds a Bachelor of Science in Biochemistry from Texas State University.

Lauren Greene joined AllCells in 2016 to develop and lead AllCells’ Donor Management Program. With a background in blood banking, Lauren brings with her an innovative approach to donor management, marketing and recruitment. Prior to joining AllCells, Lauren held many positions for 9 years at the American Red Cross where she focused on database asset management and apheresis donor recruitment. Lauren has an extensive focus on project management, new process implementation, regulated operations, system validations, and database management. Lauren holds a B.A. in English from Bridgewater State University.

Sheila Smith, Senior Director of Clinical Operations, joined AllCells in July 2014. Sheila brings over 30 years of clinical experience with specialization in therapeutic and donor apheresis, immunology, and clinical research to AllCells. Additional experience includes fiscal management, state and federal regulatory compliance, development of standard operating procedures, and quality programs.

Prior to joining AllCells, Sheila served as the Apheresis Regional Manager at Fresenius Medical Care, where she was responsible for the operations and clinical oversight of a Northern California mobile apheresis program serving over 65 hospitals and healthcare organizations. Sheila holds a B.S. in Nursing (Grand Valley State College, Allendale, MI) and a Hemapheresis Practitioner Certification through the American Society for Clinical Pathology.

Carlos Conejero is a Senior Quality Management professional offering over 14 years of cumulative experience in the areas of quality systems, quality assurance, and quality control operations management. Carlos provides solutions and promotes continuous improvements to final product and service quality, customer satisfaction within the cell therapy, medical, pharmaceutical, and biotech sector. Recently, Carlos has also held Quality leadership roles in QA, QC, and QS of increasing responsibility at Minaris Regenerative Medicine (former HCATS). Carlos holds an MBA degree from Camaguey University, School of Business, Camaguey (Cuba), and Bachelor of Science in Industrial Engineering from Universidad Central de Las Villas, Santa Clara (Cuba).

Eric joined AllCells in 2012 as part of the manufacturing team. Since then, Eric has since grown with AllCells in the areas of assay services, procurement, project management, technical-commercial support, customer success, and sales operations. Eric currently leads and direct AllCells’ operations, including production planning, production lab, and material management. Eric’s operations team carry out daily operations related to RUO and GMP-compliant cell processing. Eric holds a B.S. in Biology from UC Irvine and a M.S. in Quantitative Systems Biology from UC Merced.